Stéphane Bancel, Moderna CEO (Nancy Lane/The Boston Herald via AP Images, Pool)

Mod­er­na's boost­er plan comes in­to fo­cus with pre-print stud­ies in im­muno­com­pro­mised pop­u­la­tions, Delta break­throughs

Mod­er­na sub­mit­ted ini­tial da­ta to the FDA for its Covid-19 vac­cine boost­er plan ear­li­er this week, and that plan is sharp­en­ing in­to view fol­low­ing sev­er­al pub­lished pre-prints over the last few weeks.

Stud­ies out­lin­ing the Mod­er­na vac­cine’s ef­fec­tive­ness in dif­fer­ent im­muno­com­pro­mised pop­u­la­tions, as well as ex­am­in­ing the shots’ abil­i­ty to pre­vent break­through in­fec­tions, have come to light re­cent­ly. And most, if not all, of the pre-prints show Mod­er­na’s shot net­ting high­er rates at pre­vent­ing Covid-19 than the jab from Pfiz­er and BioN­Tech.

Mod­er­na point­ed to the stud­ies in a press brief­ing Fri­day morn­ing as like­ly to be in­clud­ed in boost­er da­ta sub­mis­sions, tout­ing its re­sults in head-to-head com­par­isons with Pfiz­er.

In a pre-print pub­lished last month look­ing at mR­NA vac­cine ef­fec­tive­ness in more than 1,500 in­di­vid­u­als on main­te­nance dial­y­sis, re­searchers ob­served a 96% sero­log­ic re­sponse among those who re­ceived two dos­es of the Mod­er­na shot. That rate com­pared to an 87% rate in pa­tients who got the Pfiz­er/BioN­Tech shot and 37% in those who re­ceived the J&J vac­cine.

Of the 1,528 peo­ple in the study, 766 re­ceived Mod­er­na shots. An­oth­er 437 pa­tients re­ceived the Pfiz­er/BioN­Tech shot, while 325 got the J&J jab.

An­oth­er pre-print post­ed in Au­gust looked at re­al-world da­ta from vac­cine re­cip­i­ents in Qatar. This study, look­ing specif­i­cal­ly at break­through in­fec­tions due to the Delta vari­ant, found the Mod­er­na shot had much high­er rates at pre­vent­ing symp­to­matic in­fec­tion than the Pfiz­er/BioN­Tech vac­cine.

As of the end of the study on Ju­ly 21, re­searchers had ob­served a 79% ef­fec­tive­ness rate 14 days af­ter one Mod­er­na shot and a 84.8% rate 14 days af­ter the sec­ond shot. Those fig­ures — ob­serv­ing any symp­to­matic break­through case — con­trast­ed with the Pfiz­er/BioN­Tech vac­cine, which saw rates of 64.2% and 53.5%, re­spec­tive­ly.

Ad­di­tion­al­ly, Mod­er­na record­ed 100% ef­fec­tive­ness at pre­vent­ing se­vere dis­ease or hos­pi­tal­iza­tion due to Delta, com­pared to 89.7% for Pfiz­er/BioN­Tech.

As with any pre-print, none of the da­ta have been peer re­viewed.

Mod­er­na an­nounced Wednes­day it had sub­mit­ted boost­er shot plans for a 50 µg dose, low­er than the 100 µg dose cur­rent­ly au­tho­rized un­der emer­gency use. Ear­li­er this week, the com­pa­ny said a 50 Xg boost­er re­sult­ed in an­ti­body titer lev­els “sig­nif­i­cant­ly above the Phase 3 bench­mark.”

The boost­er sub­mis­sion came just a week af­ter the biotech wrapped up its BLA for the orig­i­nal, two-dose reg­i­men. Pfiz­er and BioN­Tech re­ceived full ap­proval for their Covid-19 vac­cine on Aug. 23, and a boost­er shot ad­comm is planned for Sept. 17.

The new ad­comm comes amid con­cerns that Pres­i­dent Joe Biden’s ad­min­is­tra­tion had med­dled with the reg­u­la­to­ry process by un­veil­ing a na­tion­wide boost­er cam­paign ahead of any FDA re­views. The per­ceived over­reach was what, ul­ti­mate­ly, con­tributed to the sud­den de­par­tures of two top of­fi­cials who have been lead­ing the agency’s vac­cine re­view for years, a for­mer se­nior FDA leader said.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jay Bradner (Jeff Rumans for Endpoints News)

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

Right about a year ago, a Novartis team led by Jay Bradner and Cynthia Grosskreutz at NIBR swooped in to scoop up a Cambridge, MA-based opthalmology gene therapy company called Vedere. Their focus was on a rather narrow market niche: inherited retinal dystrophies that include a wide range of genetic retinal disorders marked by the loss of photoreceptor cells and progressive vision loss.

But that was just the first deal that whet their appetite.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

President Biden and Pfizer CEO Albert Bourla (Patrick Semansky/AP Images)

Chaot­ic ad­comm sees Pfiz­er/BioN­Tech boost­ers re­ject­ed for gen­er­al pop­u­la­tion, but rec­om­mend­ed for old­er and high-risk pop­u­la­tions

With just days before President Joe Biden’s Covid-19 booster rollout is set to go into effect, an FDA advisory committee appeared on the verge of not recommending boosters for anyone in the US before a last-minute change of wording laid the groundwork for older adults to have access to a third dose.

The FDA’s adcomm on Vaccines and Related Biological Products (VRBPAC) roundly rejected Pfizer/BioNTech booster shots for all individuals older than 16 by a 16-2 vote Friday afternoon. Soon after, however, the agency posed committee members a new question limiting booster use to the 65-and-older population and individuals at high risk of disease due to occupational exposure or comorbidities.

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.